{
    "xml": "<topic id=\"PHP3010\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/clonazepam\" basename=\"clonazepam\" title=\"CLONAZEPAM\">\n<title>CLONAZEPAM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_408\" namespace=\"/interactions/list-of-drug-interactions/anxiolytics-and-hypnotics/benzodiazepines/clonazepam\">Clonazepam</xref>\n</p>\n<data name=\"vtmid\">69708003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_916643688\" title=\"Hypnotics and sedatives (benzodiazepine)\">Hypnotics and sedatives (benzodiazepine)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34584\" title=\"BENZODIAZEPINES\" namespace=\"/drug-classes/benzodiazepines\">BENZODIAZEPINES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP47178\" outputclass=\"indicationsAndDose\" rev=\"1.39\" parent=\"/drugs/clonazepam\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">All forms of epilepsy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;11 months</p>\n<p>Initially 250&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 0.5&#8211;1&#8239;mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;4 years</p>\n<p>Initially 250&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 1&#8211;3&#8239;mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;11 years</p>\n<p>Initially 500&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 3&#8211;6&#8239;mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 1&#8239;mg once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8&#8239;mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1&#8239;mg once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8&#8239;mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 500&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8&#8239;mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47105\" outputclass=\"unlicensedUse\" rev=\"1.13\" parent=\"/drugs/clonazepam\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Clonazepam doses in BNFC may differ from those in product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Clonazepam doses in BNF may differ from those in product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47249\" outputclass=\"contraindications\" rev=\"1.11\" parent=\"/drugs/clonazepam\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Coma</ph>; <ph outputclass=\"contraindication\">current alcohol abuse</ph>; <ph outputclass=\"contraindication\">current drug abuse</ph>; <ph outputclass=\"contraindication\">respiratory depression</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47255\" outputclass=\"cautions\" rev=\"1.30\" parent=\"/drugs/clonazepam\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">airways obstruction</ph>; <ph outputclass=\"caution\">brain damage</ph>; <ph outputclass=\"caution\">cerebellar ataxia</ph>; <ph outputclass=\"caution\">depression</ph>; <ph outputclass=\"caution\">spinal ataxia</ph>; <ph outputclass=\"caution\">suicidal ideation</ph>\r\n</p>\r\n </section>\r\n<section outputclass=\"importantAdvice\">\r\n<title>Cautions, further information</title>\r\n<sectiondiv>\r\n<p>The effectiveness of clonazepam may decrease significantly after weeks or months of continuous therapy.</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP47127\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/clonazepam\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Amnesia</ph>; <ph outputclass=\"sideEffect\">bronchial hypersecretion in infants and small children</ph>; <ph outputclass=\"sideEffect\">co-ordination disturbances</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">dependence</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">muscle hypotonia</ph>; <ph outputclass=\"sideEffect\">nystagmus</ph>; <ph outputclass=\"sideEffect\">poor concentration</ph>; <ph outputclass=\"sideEffect\">restlessness</ph>; <ph outputclass=\"sideEffect\">salivary hypersecretion in infants and small children</ph>; <ph outputclass=\"sideEffect\">withdrawal symptoms</ph> (in children)</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Aggression</ph>; <ph outputclass=\"sideEffect\">anxiety</ph>; <ph outputclass=\"sideEffect\">blood disorders</ph>; <ph outputclass=\"sideEffect\">dysarthria</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal symptoms</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">paradoxical effects</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">respiratory depression</ph>; <ph outputclass=\"sideEffect\">reversible hair loss</ph>; <ph outputclass=\"sideEffect\">sexual dysfunction</ph>; <ph outputclass=\"sideEffect\">skin pigmentation changes</ph>; <ph outputclass=\"sideEffect\">suicidal ideation</ph> (in adults); <ph outputclass=\"sideEffect\">urinary incontinence</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>; <ph outputclass=\"sideEffect\">visual disturbances on long-term treatment</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Increase in seizure frequency</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47253\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/clonazepam\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Prescribers should consider carefully the choice of antiepileptic therapy in pre-pubescent girls who may later become pregnant.</p>\n<p>Women of child-bearing potential who take antiepileptic drugs should be given contraceptive advice. Some antiepileptic drugs can reduce the efficacy of hormonal contraceptives, and the efficacy of some antiepileptics may be affected by hormonal contraceptives.</p>\n<p>Women who want to become pregnant should be referred to a specialist for advice in advance of conception. For some women, the severity of seizure or the seizure type may not pose a serious threat, and drug withdrawal may be considered; therapy may be resumed after the first trimester. If treatment with antiepileptic drugs must continue throughout pregnancy, then monotherapy is preferable at the lowest effective dose.</p>\n<p>To reduce the risk of neural tube defects, folate supplementation is advised before conception.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47162\" outputclass=\"pregnancy\" parent=\"/drugs/clonazepam\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"additionalMonitoringInPregnancy\">\n<sectiondiv>\n<p>Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.</p>\n<p>The concentration of antiepileptic drugs in the plasma can change during pregnancy. The dose of antiepileptic drugs should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.</p>\n<p>Plasma-drug concentration monitoring during pregnancy is also useful to check compliance.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47258\" outputclass=\"breastFeeding\" parent=\"/drugs/clonazepam\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk, and should be avoided if possible during breast-feeding.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInBreastFeeding\">\n<sectiondiv>\n<p>All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47203\" outputclass=\"hepaticImpairment\" parent=\"/drugs/clonazepam\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with smaller initial doses or reduce dose.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47150\" outputclass=\"renalImpairment\" parent=\"/drugs/clonazepam\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47099\" outputclass=\"monitoringRequirements\" parent=\"/drugs/clonazepam\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p outputclass=\"title\">Monitoring</p>\n<p>Routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals. However, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity. Similarly, haematological and biochemical monitoring should not be undertaken unless clinically indicated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47109\" outputclass=\"treatmentCessation\" rev=\"1.18\" parent=\"/drugs/clonazepam\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Drugs should be gradually withdrawn over at least 2&#8211;3 months by reducing the daily dose by 10&#8211;25% at intervals of 1&#8211;2 weeks. Benzodiazepines may need to be withdrawn over 6 months or longer.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal because this can precipitate severe rebound seizures. Reduction in dosage should be gradual.</p>\n<p>The decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal.</p>\n<p>In patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57768\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.16\" parent=\"/drugs/clonazepam\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Switching between formulations</p>\n<p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p>\n<p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic oral clonazepam product.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use in children</p>\n<p>Liquid preparations available from 'special order' manufacturers or specialist importing companies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47155\" outputclass=\"patientAndCarerAdvice\" rev=\"1.28\" parent=\"/drugs/clonazepam\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\r\n<title>Driving and skilled tasks</title>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Driving</p>\r\n<p>Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.</p>\r\n<p>Guidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.</p>\r\n<p>Patients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Clonazepam for preventing seizures</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0\">www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0</xref>\n</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3010-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/clonazepam\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral drops, oral solution, orodispersible tablet</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77334\" title=\"Tablet\" namespace=\"/drugs/clonazepam/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77381\" title=\"Oral solution\" namespace=\"/drugs/clonazepam/oral-solution\">Oral solution</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78230\" namespace=\"/treatment-summaries/epilepsy\" title=\"Epilepsy\" count=\"4\" rel=\"backlink\">Epilepsy</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_408\" namespace=\"/interactions/list-of-drug-interactions/anxiolytics-and-hypnotics/benzodiazepines/clonazepam\" title=\"Clonazepam\" count=\"1\" rel=\"link\">Clonazepam</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34584\" namespace=\"/drug-classes/benzodiazepines\" title=\"BENZODIAZEPINES\" count=\"1\" rel=\"link\">BENZODIAZEPINES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77334\" namespace=\"/drugs/clonazepam/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77381\" namespace=\"/drugs/clonazepam/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n</links>\n</topic>",
    "id": "PHP3010",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/clonazepam",
    "basename": "clonazepam",
    "title": "CLONAZEPAM",
    "interactants": [
        {
            "id": "bnf_int_408",
            "label": "Clonazepam"
        }
    ],
    "vtmid": "69708003",
    "drugClassification": [
        "Hypnotics and sedatives (benzodiazepine)"
    ],
    "inheritsFromClass": [
        "BENZODIAZEPINES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "All forms of epilepsy",
                        "html": "All forms of epilepsy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 250 micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 0.5&#8211;1 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.",
                        "html": "<p>Initially 250&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 0.5&#8211;1&#8239;mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.</p>",
                        "ageGroup": "1&#8211;11 months"
                    },
                    {
                        "textContent": "Initially 250 micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 1&#8211;3 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.",
                        "html": "<p>Initially 250&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 1&#8211;3&#8239;mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.</p>",
                        "ageGroup": "1&#8211;4 years"
                    },
                    {
                        "textContent": "Initially 500 micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 3&#8211;6 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.",
                        "html": "<p>Initially 500&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 3&#8211;6&#8239;mg daily, dose to be taken at night; may be given in 3 divided doses if necessary.</p>",
                        "ageGroup": "5&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 1 mg once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.",
                        "html": "<p>Initially 1&#8239;mg once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8&#8239;mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 1 mg once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.",
                        "html": "<p>Initially 1&#8239;mg once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8&#8239;mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.</p>"
                    },
                    {
                        "textContent": "Initially 500 micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.",
                        "html": "<p>Initially 500&#8239;micrograms once daily for 4 nights, dose to be increased over 2&#8211;4 weeks, usual dose 4&#8211;8&#8239;mg daily, adjusted according to response, dose usually taken at night; may be given in 3&#8211;4 divided doses if necessary.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Clonazepam doses in BNFC may differ from those in product literature.",
                "html": "<p>Clonazepam doses in BNFC may differ from those in product literature.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Clonazepam doses in BNF may differ from those in product literature.",
                "html": "<p>Clonazepam doses in BNF may differ from those in product literature.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Coma",
                "html": "Coma"
            },
            {
                "type": "contraindications",
                "textContent": "current alcohol abuse",
                "html": "current alcohol abuse"
            },
            {
                "type": "contraindications",
                "textContent": "current drug abuse",
                "html": "current drug abuse"
            },
            {
                "type": "contraindications",
                "textContent": "respiratory depression",
                "html": "respiratory depression"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "airways obstruction",
                "html": "airways obstruction"
            },
            {
                "type": "cautions",
                "textContent": "brain damage",
                "html": "brain damage"
            },
            {
                "type": "cautions",
                "textContent": "cerebellar ataxia",
                "html": "cerebellar ataxia"
            },
            {
                "type": "cautions",
                "textContent": "depression",
                "html": "depression"
            },
            {
                "type": "cautions",
                "textContent": "spinal ataxia",
                "html": "spinal ataxia"
            },
            {
                "type": "cautions",
                "textContent": "suicidal ideation",
                "html": "suicidal ideation"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "The effectiveness of clonazepam may decrease significantly after weeks or months of continuous therapy.",
                "html": "<p>The effectiveness of clonazepam may decrease significantly after weeks or months of continuous therapy.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Amnesia",
                        "html": "Amnesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bronchial hypersecretion in infants and small children",
                        "html": "bronchial hypersecretion in infants and small children",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "co-ordination disturbances",
                        "html": "co-ordination disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dependence",
                        "html": "dependence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "muscle hypotonia",
                        "html": "muscle hypotonia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nystagmus",
                        "html": "nystagmus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "poor concentration",
                        "html": "poor concentration",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "restlessness",
                        "html": "restlessness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "salivary hypersecretion in infants and small children",
                        "html": "salivary hypersecretion in infants and small children",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "withdrawal symptoms in children",
                        "html": "withdrawal symptoms in children",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common",
                            "patientType": "children"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Aggression",
                        "html": "Aggression",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "anxiety",
                        "html": "anxiety",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "blood disorders",
                        "html": "blood disorders",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "dysarthria",
                        "html": "dysarthria",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "gastro-intestinal symptoms",
                        "html": "gastro-intestinal symptoms",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "paradoxical effects",
                        "html": "paradoxical effects",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "respiratory depression",
                        "html": "respiratory depression",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "reversible hair loss",
                        "html": "reversible hair loss",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "sexual dysfunction",
                        "html": "sexual dysfunction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "skin pigmentation changes",
                        "html": "skin pigmentation changes",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "suicidal ideation in adults",
                        "html": "suicidal ideation in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "urinary incontinence",
                        "html": "urinary incontinence",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "visual disturbances on long-term treatment",
                        "html": "visual disturbances on long-term treatment",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Increase in seizure frequency",
                        "html": "Increase in seizure frequency",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Prescribers should consider carefully the choice of antiepileptic therapy in pre-pubescent girls who may later become pregnant.\n\nWomen of child-bearing potential who take antiepileptic drugs should be given contraceptive advice. Some antiepileptic drugs can reduce the efficacy of hormonal contraceptives, and the efficacy of some antiepileptics may be affected by hormonal contraceptives.\n\nWomen who want to become pregnant should be referred to a specialist for advice in advance of conception. For some women, the severity of seizure or the seizure type may not pose a serious threat, and drug withdrawal may be considered; therapy may be resumed after the first trimester. If treatment with antiepileptic drugs must continue throughout pregnancy, then monotherapy is preferable at the lowest effective dose.\n\nTo reduce the risk of neural tube defects, folate supplementation is advised before conception.",
                "html": "<p>Prescribers should consider carefully the choice of antiepileptic therapy in pre-pubescent girls who may later become pregnant.</p><p>Women of child-bearing potential who take antiepileptic drugs should be given contraceptive advice. Some antiepileptic drugs can reduce the efficacy of hormonal contraceptives, and the efficacy of some antiepileptics may be affected by hormonal contraceptives.</p><p>Women who want to become pregnant should be referred to a specialist for advice in advance of conception. For some women, the severity of seizure or the seizure type may not pose a serious threat, and drug withdrawal may be considered; therapy may be resumed after the first trimester. If treatment with antiepileptic drugs must continue throughout pregnancy, then monotherapy is preferable at the lowest effective dose.</p><p>To reduce the risk of neural tube defects, folate supplementation is advised before conception.</p>"
            }
        ]
    },
    "pregnancy": {
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.\n\nThe concentration of antiepileptic drugs in the plasma can change during pregnancy. The dose of antiepileptic drugs should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.\n\nPlasma-drug concentration monitoring during pregnancy is also useful to check compliance.",
                "html": "<p>Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.</p><p>The concentration of antiepileptic drugs in the plasma can change during pregnancy. The dose of antiepileptic drugs should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.</p><p>Plasma-drug concentration monitoring during pregnancy is also useful to check compliance.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk, and should be avoided if possible during breast-feeding.",
                "html": "<p>Present in milk, and should be avoided if possible during breast-feeding.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.",
                "html": "<p>All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with smaller initial doses or reduce dose.",
                "html": "<p>Start with smaller initial doses or reduce dose.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.\n\nAvoid in severe impairment.",
                "html": "<p>Can precipitate coma.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe impairment.",
                "html": "<p>Start with small doses in severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Monitoring",
                "textContent": "Routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals. However, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity. Similarly, haematological and biochemical monitoring should not be undertaken unless clinically indicated.",
                "html": "<p>Routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals. However, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity. Similarly, haematological and biochemical monitoring should not be undertaken unless clinically indicated.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Drugs should be gradually withdrawn over at least 2&#8211;3 months by reducing the daily dose by 10&#8211;25% at intervals of 1&#8211;2 weeks. Benzodiazepines may need to be withdrawn over 6 months or longer.",
                "html": "<p>Drugs should be gradually withdrawn over at least 2&#8211;3 months by reducing the daily dose by 10&#8211;25% at intervals of 1&#8211;2 weeks. Benzodiazepines may need to be withdrawn over 6 months or longer.</p>"
            },
            {
                "type": "treatmentCessation",
                "textContent": "Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal because this can precipitate severe rebound seizures. Reduction in dosage should be gradual.\n\nThe decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal.\n\nIn patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.",
                "html": "<p>Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal because this can precipitate severe rebound seizures. Reduction in dosage should be gradual.</p><p>The decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal.</p><p>In patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "title": "Switching between formulations",
                "textContent": "Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.\n\nPatients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic oral clonazepam product.",
                "html": "<p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p><p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic oral clonazepam product.</p>"
            },
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "With oral use in children",
                    "html": "With <ph outputclass=\"route\">oral</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Liquid preparations available from 'special order' manufacturers or specialist importing companies.",
                "html": "<p>Liquid preparations available from 'special order' manufacturers or specialist importing companies.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Driving",
                "textContent": "Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.\n\nGuidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.\n\nPatients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.",
                "html": "<p>Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.</p><p>Guidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.</p><p>Patients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.</p>"
            }
        ],
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0",
                        "label": "www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Clonazepam for preventing seizures",
                "textContent": "www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0\">www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0</xref>\n</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral drops",
                "oral solution",
                "orodispersible tablet"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77334",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77381",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78230",
                "label": "Epilepsy",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_408",
                "label": "Clonazepam",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34584",
                "label": "BENZODIAZEPINES",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77334",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77381",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    }
}